$2.34
-0.21(-8.24%)
Mkt Cap $20M
$2.01
$9.15
52-Week Range
At a Glance
AI-generatedNasus Pharma Ltd.
6-K
Nasus Pharma announced positive Phase 2 topline results for NS002 intranasal epinephrine, demonstrating statistically significant improvements in early absorption versus EpiPen, with a pivotal study planned for Q4 2026. The company reported 2025 annual results including $4.3 million cash and $5.9 million net loss, with cash runway to Q2 2027 following $15 million private placement.$20M
Market Cap
—
Revenue
—
Net Income
Employees2
Fundamentals
How The Business Makes Money
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0002029039
ISINIL0012181553
CUSIP001218155
Phone97235736632
AddressYigal Alon 65, Tel Aviv, 6744317, IL
SEC EDGAR